Atellica DCA Analyzer Diabetes testing, evolved


siemens-healthineers.com/atellica-dca-analyzer



What if you could diagnose diabetes early and regularly monitor your patients?

More than 537 million people around the world have diabetes¹


Diabetes is one of the largest global-health emergencies of the 21st century. It continues to grow in prevalence but remains largely undetected.





A 1% reduction in HbA1c may reduce amputation or death caused by blocked blood vessels by 43% and reduce instance of heart attack by 14%.²

Studies show that HbA1c levels reduce faster with point-of-care (POC) testing.³



University of Texas Medical Branch Galveston, TX

Routine POC diabetes testing can improve patient outcomes and help meet KPIs

Siemens Healthineers solutions help providers achieve better results for clinics and patients.

High patient-satisfaction scores: 3.96 out of 4.0

Studies demonstrated flexible and improved patient workflows, which led to productive patient dialogue.

Improving care plans led to high patient-satisfaction scores: 3.96 out of $4.0.^{4,5}$

Help improve patient glycemic control and identify early kidney disease

Studies have shown an overall reduction in A1c levels by as much as 35% for patients monitored with POC HbA1c testing vs. the lab.^{3,5}


POC albumin:creatinine ratio (ACR) testing identified 45% of patients with abnormal levels who needed immediate follow-up care.⁶

Proven to have a positive financial impact of \$24.65 per patient

In a study using POC HbA1c analyzers, testing was shown to lower operational costs by optimizing clinical operations and thereby reducing follow-up phone calls/letters and patient revisits.⁴

Help increase rate of early diagnoses

The use of a POC HbA1c test vs. standard practices greatly increases the likelihood of screening adults for diabetes.⁷











Atellica DCA Analyzer Compact. Portable. Scalable. Customizable.

Building upon one of the industry's most trusted technologies for diabetes testing, the Atellica[®] DCA Analyzer puts fast, quality results right at your fingertips. Experience the performance and precision you need to improve outcomes, and get the speed, standardization, and personalization you want to boost efficiencies and meet growing demand.



Freedom to optimize your workflows and evolve your POC experience

Freedom




Confidence Gain confidence with results you can trust

Trusted performance

• Lab-quality* results using technology with 30+ years of proven clinical reliability.

• Atellica DCA Analyzer strongly correlated to results from the Tosoh G8 laboratory method.⁸



- No clinically significant interferences from common hemoglobin variants for HbA1c measurements.⁹
- Atellica DCA HbA1c test is not affected by hemolyzed samples and can help reduce preanalytical errors.

Built-in safeguards

Auto-Checks[™] technology ensures accurate sample processing and reliable results, and built-in risk mitigation features provide an audit-ready solution.



Liquid ready controls help prevent pre-analytical errors.



Security measures protect patient data.

- No patient data transmitted between display and module.
- Operator access control prevents unauthorized access.
- Operator lockout after five failed attempts.
- TLS encryption protects from cybersecurity threats.
- USB debugging port is disabled.
- Manually exported data is passwordprotected.

Intuitive user interface

Simple operation and an intuitive UI decrease the likelihood of operator error, improve user experience, and reduce training complexity.



*Results comparable or equivalent to those produced by core laboratory equipment.

Improve overall patient experience and outcomes

Better

Patient Outcomes

Rapid results

HbA1c results are available in 5 minutes, ensuring timely patient consultation and treatment path.



Positive patient experience

Small sample size, sufficient sample hold time, and the ability to process hemolyzed samples mitigate pre-analytical errors and reduce patient discomfort from re-sticks.




Enhanced patient conversations

Built-in patient trend graphs complement patient consultations and aid in clinical decision making.

"POCT can significantly improve clinical operations with cost reductions through improved practice efficiency. The economic benefits of POCT may be realized in both fee-for-service and global payment environments."

J. Benjamin Crocker, MD

Medical Director, Ambulatory Practice of the Future Massachusetts General Hospital, Boston, MA



Dr. Henk Veese Pediatric Diabetologist and Co-founder Diabeter Treatment Program, Rotterdam, Netherlands

A legacy of innovation and impact

30yrs of trusted immunoassay technology



peer-reviewed articles and clinical citations

NGSP- and IFCC-certified annually

At Siemens Healthineers, we pioneer breakthroughs in healthcare. For everyone. Everywhere. By constantly bringing breakthrough innovations to market, we enable healthcare professionals to deliver high-quality care, leading to the best possible outcome for patients.

Our portfolio, spanning from in-vitro and in-vivo diagnostics to image-guided therapy and innovative cancer care, is crucial for clinical decision-making and treatment pathways. With our strengths in patient twinning, precision therapy, as well as digital, data, and artificial intelligence (AI), we are well positioned to take on the biggest challenges in healthcare. We will continue to build on these strengths to help fight the world's most threatening diseases, improving the quality of outcomes, and enabling access to care.

We are a team of 66,000 highly dedicated employees across more than 70 countries passionately pushing the boundaries of what's possible in healthcare to help improve people's lives around the world.

Atellica, Auto-Checks, DCA, and all associated marks are trademarks of Siemens Healthcare Diagnostics Inc., or its affiliates. All other trademarks and brands are the property of their respective owners.

Not available for sale in the U.S.A. Product availability may vary from country to country and is subject to varying regulatory requirements. Please contact your local representative for availability.

References:

- International Diabetes Federation.
 IDF diabetes atlas. 10th edition. Available from: http://www.diabetesatlas.org/.
- 2. Stratton, et al. BMJ. 2000;21:405-12.
- Petersen J, et al. Effect of point-of-care on maintenance of glycemic control as measured by A1c. Diabetes Care. 2007 Mar;30(3).
- 4. Crocker, et al. Patient satisfaction with point-of-care laboratory testing: report of a quality improvement program in an ambulatory practice of an academic medical center. Clinica Chimica Acta. 2013;424:8-11.
- 5. Schnell, et al. Impact of HbA1c testing at point of care on diabetes management. Journal of Diabetes Science and Technology. 2017;11(3):611-17.
- 6. Murtuza MM, et al. POD2ER: Prevention and Organization against Diabetes Dialysis with Education and Resources. Kidney Dis. 55:181-91.
- 7. www.annfammed.org/content/15/2/162. full.pdf.
- 8. Siemens Healthcare Diagnostics Inc. Internal study conducted at Western Michigan University School of Medicine. 2019.
- 9. http://www.ngsp.org/interf.asp.

Siemens Healthineers Headquarters

Siemens Healthcare GmbH Henkestr. 127 91052 Erlangen, Germany Phone: +49 913184-0 siemens-healthineers.com

Published by

Siemens Healthcare Diagnostics Inc. Point of Care Diagnostics 2 Edgewater Drive Norwood, MA 02062-4637 USA Phone: +1 781-269-3000